Some researchers believe DMT, a powerful psychedelic that may naturally occur in the brain, could be your soul’s “ferryman.” ...

that is advancing a psychedelic program investigating a proprietary form of sub-psychedelic DMT for stroke and traumatic brain injury. www.algernonpharmaceuticals.com. The CSE does not accept ...

Validcare CEO Patrick McCarthy said, “We are very excited to be working with Algernon Neuro on their upcoming, ground-breaking Phase 2a DMT stroke study and we are very pleased to become an ...

that is advancing a psychedelic program investigating a proprietary form of sub-psychedelic DMT for stroke and traumatic brain injury. [email protected] [email protected ...

that is advancing a psychedelic program investigating a proprietary form of sub-psychedelic DMT for stroke and traumatic brain injury. info@algernonpharmaceuticals.com investors@ ...

that is advancing a psychedelic program investigating a proprietary form of sub-psychedelic DMT for stroke and traumatic brain injury. www.algernonpharmaceuticals.com. The CSE does not accept ...

that is advancing a psychedelic program investigating a proprietary form of sub-psychedelic DMT for stroke and traumatic brain injury. Neither the Canadian Securities Exchange nor its Market Regulator ...

placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe. The study is expected to begin enrolling patients in Q3 of 2025. Validcare is a leading U.S. based full service CRO with ...

that is advancing a psychedelic program investigating a proprietary form of sub-psychedelic DMT for stroke and traumatic brain injury. Christopher J. MoreauCEOAlgernon Pharmaceuticals Inc.604.398.4175 ...

I set out on a 3 ½-week trip to Japan. The timing worked out — the favorable dollar-to-yen exchange rate, mild weather, and vibrant autumn foliage made it a great time to visit. With little ...